Arecor Therapeutics plc (AREC.L)
GBp 38.0
(0.0%)
GBp 38.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -8.39 Million GBP | 4.81% |
| 2022 | -10.06 Million GBP | -61.76% |
| 2021 | -6.26 Million GBP | -92.85% |
| 2020 | -3.25 Million GBP | -24.93% |
| 2019 | -2.61 Million GBP | 2.56% |
| 2018 | -2.67 Million GBP | -118.8% |
| 2017 | -1.22 Million GBP | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.3 Million GBP | 0.0% |
| 2024 Q1 | -2.3 Million GBP | -13.15% |
| 2023 Q4 | -2.03 Million GBP | -1.27% |
| 2023 FY | - GBP | 4.81% |
| 2023 Q2 | -5.26 Million GBP | -126.17% |
| 2023 Q3 | -2.01 Million GBP | 61.8% |
| 2023 Q1 | -2.32 Million GBP | 60.24% |
| 2022 Q2 | -5.56 Million GBP | -116.7% |
| 2022 Q1 | -2.56 Million GBP | 35.48% |
| 2022 Q4 | -5.85 Million GBP | -133.98% |
| 2022 FY | - GBP | -61.76% |
| 2022 Q3 | -2.5 Million GBP | 55.07% |
| 2021 Q3 | -1.48 Million GBP | 49.27% |
| 2021 Q2 | -2.92 Million GBP | -103.58% |
| 2021 FY | - GBP | -92.85% |
| 2021 Q1 | -1.43 Million GBP | 32.88% |
| 2021 Q4 | -3.98 Million GBP | -168.34% |
| 2020 Q3 | -1 Million GBP | 35.72% |
| 2020 Q2 | -1.57 Million GBP | -155.78% |
| 2020 Q1 | -614.23 Thousand GBP | 0.0% |
| 2020 FY | - GBP | -24.93% |
| 2020 Q4 | -2.14 Million GBP | -112.0% |
| 2019 FY | - GBP | 2.56% |
| 2018 FY | - GBP | -118.8% |
| 2017 FY | - GBP | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|